Inaktiver Wert

Andere Sprachen Jupiter Neurosciences, Inc.

Aktien

Jupiter Neurosciences, Inc. Announces Research Breakthrough with JOTROL in Parkinson's Disease	27.02.23
Jupiter Neurosciences, Inc. Announces Appointment of New Chief Financial Officer	13.01.23
Jupiter Neurosciences, Inc. Appoints Saleem Elmasri as Chief Financial Officer	12.01.23
Jupiter Neurosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	02.12.22
Jupiter Neurosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	16.08.22
Jupiter Neurosciences, Inc. Announces Journal of Alzheimer's Disease Publication Highlighting Use of JOTROL™	14.06.22
Jupiter Neurosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	18.05.22
Jupiter Neurosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	26.04.22
Jupiter Neurosciences, Inc. Auditor Raises 'Going Concern' Doubt	26.04.22
Jupiter Neurosciences, Inc. Announces Broadening of IP Estate for its Unique Resveratrol Formulation, JOTROL	01.03.22
Jupiter Neurosciences, Inc. Announces Completion of Phase I Safety Trial with Enhanced Resveratrol Product, JOTROL™	23.02.22
Jupiter Neurosciences to Issue 2.2 Million Units in IPO	27.01.22
Jupiter Neurosciences, Inc. has filed an IPO.	12.10.21
Jupiter Neurosciences, Inc. Auditor Raises 'Going Concern' Doubt	12.10.21
Jupiter Neurosciences, Inc. Announces New Corporate Offices	21.09.21

Keine Ergebnisse zu dieser Suche